pubmed.ncbi.nlm.nih.gov

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials - PubMed

Review

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

A Lazo-Langner et al. J Thromb Haemost. 2007 Apr.

Free article

Abstract

Background: Low-molecular-weight heparins (LMWH) have an antitumor effect in vitro and in experimental animal models of malignancy. Retrospective data suggest that it might improve survival in cancer patients.

Objectives: To evaluate the effect of LMWH compared to placebo or no anticoagulant intervention on the survival of cancer patients.

Methods: We conducted a systematic review of randomized trials specifically evaluating the impact of LMWH on the survival of cancer patients. DATA SOURCES WERE: MEDLINE, EMBASE, HealthSTAR, Cochrane library, gray literature and cross-referencing from reference lists. Data extraction was performed by one reviewer, and accuracy was independently verified by a second reviewer. Meta-analysis was conducted using: (i) odds ratio (OR) and relative risk (RR); (ii) survival rates using censored endpoints; and (iii) hazard ratios (HR).

Results: The pooled HR in all patients was 0.83 (95% CI 0.70-0.99; P = 0.03), and in patients with advanced disease it was 0.86 (95% CI 0.74-0.99; P = 0.04), both in favor of the LMWH group. The results of the OR, RR and survival meta-analysis consistently favored the LMWH group. Sensitivity analyses according to tumor type were not conducted, because of a lack of information.

Conclusions: LMWH improves overall survival in cancer patients, even in those with advanced disease. Additional trials are required to define the tumor types, disease stages and dosing schedules most likely to provide the greatest survival benefit.

PubMed Disclaimer

Cited by

Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase.
Luengo-Gil G, Calvo MI, Martín-Villar E, Águila S, Bohdan N, Antón AI, Espín S, Ayala de la Peña F, Vicente V, Corral J, Quintanilla M, Martínez-Martínez I. Luengo-Gil G, et al. Sci Rep. 2016 Jun 8;6:27544. doi: 10.1038/srep27544. Sci Rep. 2016. PMID: 27270881 Free PMC article.
Heparin: Past, Present, and Future.
Oduah EI, Linhardt RJ, Sharfstein ST. Oduah EI, et al. Pharmaceuticals (Basel). 2016 Jul 4;9(3):38. doi: 10.3390/ph9030038. Pharmaceuticals (Basel). 2016. PMID: 27384570 Free PMC article. Review.
Venous thromboembolism and cancer: a systematic review.
Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Rodrigues CA, et al. J Thromb Thrombolysis. 2010 Jul;30(1):67-78. doi: 10.1007/s11239-010-0441-0. J Thromb Thrombolysis. 2010. PMID: 20140479 Review.
Label-Free Detection and Characterization of Heparin-Induced Thrombocytopenia (HIT)-like Antibodies.
Khan NZ, Chen LY, Lindenbauer A, Pliquett U, Rothe H, Nguyen TH. Khan NZ, et al. ACS Omega. 2021 Sep 29;6(40):25926-25939. doi: 10.1021/acsomega.1c02496. eCollection 2021 Oct 12. ACS Omega. 2021. PMID: 34660955 Free PMC article.
Haemophilia and cancer: a personal perspective.
Franchini M. Franchini M. Blood Transfus. 2013 Jan;11(1):26-31. doi: 10.2450/2012.0149-11. Epub 2012 Jul 4. Blood Transfus. 2013. PMID: 22790273 Free PMC article. Review. No abstract available.

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials - PubMed